- Home
- BEDU vs NRXP Comparison
BEDU vs NRXP Comparison
Compare BEDU & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEDU | NRXP |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 73.7M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | BEDU | NRXP |
|---|---|---|
| Price | $2.19 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 4.8K | ★ 447.9K |
| Earning Date | 01-23-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $224,321,752.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $1.15 |
| 52 Week High | $2.28 | $6.01 |
Technical Indicators
Market Signals| Indicator | BEDU | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 47.83 |
| Support Level | $2.14 | $2.22 |
| Resistance Level | $2.22 | $2.53 |
| Average True Range (ATR) | 0.03 | 0.20 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 43.75 | 72.58 |
Price Performance
Historical ComparisonAbout BEDU Bright Scholar Education Holdings Limited each representing four
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom and the United States. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.